BioLeap > Collaborations > Internal Programs Currently Available for Collaboration

Internal Programs Available for Collaboration

Although BioLeap’s technology platform is applicable to any target with a high quality crystal structure, there are targets that are particularly amenable to our platform and experience. Listed below are targets, not already committed to a collaborator, that are in various stages of internal development.

If you are interested in any of these targets, please contact us to discuss a possible collaboration.
Oncology:
1. Jak2
2. PARP
3. V500E B-Raf
4. Hsp90
5. Akt
6. B-catenin-TCF4 interaction
Antibacterial:
1. DNA gyrase
2. Mur C,D,E,F competitive inhibitor
3. Dihydropteroate synthase

Metabolic:
1. PTB1B
2. PCSK9
3. GSK-3
Inflammation:
1. Jak3
2. TNF-α trimerization
Other:
1. Neuramidase (antiviral)
2. Renin (hypertension)
3. Glucocerebrosidase (Gaucher’s, Parkinson’s)
4. BACE (Alzheimer’s)
5. Fatty acid amide hydrolase (CNS-analgesic pain)